Skip to main content

Advertisement

SpringerLink
Log in

Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study

A Case–Control Study

  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

The purpose of the study was to explore the association between plasma platelet activating factor (PAF) and platelet activating factor acetylhydrolase (PAF-AH) levels and risk of coronary heart disease (CHD) or blood stasis syndrome (BSS) of CHD. Questionnaire, routine clinical assays and plasma levels of PAF, PAF-AH and inflammatory factors hs-CRP and IL-6 were investigated or measured for 120 controls and 150 CHD patients (66 non-BSS and 84 BSS). Plasma PAF levels were higher in CHD patients [49.7 (34.8–73.2 pg/mL)] than in controls [23.8 (14.9–42.3 pg/mL)] (P < 0.001), and in BSS [56.0 (40.1–86.1 pg/mL)] than in non-BSS [47.4 (29.0–67.4 pg/mL)] (P = 0.027). Similarly, plasma PAF-AH levels were higher in CHD patients [11.5 (7.5–15.6 μmol/L)] than in controls [8.1 (5.4–12.6 μmol/L)] (P < 0.001), and in BSS [13.4 (8.7–18.5 μmol/L)] than in non-BSS [9.5 (7.3–14.3 μmol/L)] (P = 0.014). After adjustment for the confounded effects of inflammatory factors or conventional risk factors, plasma PAF and PAF-AH levels still had a significant difference between CHD patients and controls, but plasma PAF-AH rather than PAF levels had a significant difference between BSS and non-BSS. Elevated plasma PAF level contributed to the risk of CHD rather than BSS, and elevated plasma PAF-AH level was an independent risk factor of CHD and BSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

APTT:

Activated partial thromboplastin time

BMI:

Body mass index

BSS:

Blood stasis syndrome

CHD:

Coronary heart disease

95 % CI:

95 % confidence interval

ECG:

Electrocardiography

ELSA:

Enzyme-linked immunosorbent assay

HDL-C:

High density lipoprotein cholesterol

hs-CRP:

High sensitivity C-reaction protein

IL-6:

Interleukin 6

LDL-C:

Low density lipoprotein cholesterol

LP-PLA2:

Lipoprotein-associated phospholipase A2

OR:

Odds ratio

PAF:

Platelet activating factor

PAF-AH:

Platelet activating factor acetylhydrolase

PT:

Prothrombin time

SD:

Standard deviation

TC:

Total cholesterol

TCM:

Traditional Chinese medicine

TG:

Triglycerides

References

  1. Ross, R. 1999. Atherosclerosis: an inflammatory disease. The New England Journal of Medicine 340(2): 115–126.

    Article  PubMed  CAS  Google Scholar 

  2. Blake, G.J., and P.M. Rider. 2002. Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine 252: 283–294.

    Article  PubMed  CAS  Google Scholar 

  3. Welch, E.J., R.P. Nalkawadi, Z. Li, P. Lin, S. Ishii, et al. 2009. Opposing effects of platelet-activating factor and lyso-platelet activating factor on neutrophil and platelet activation. Molecular Pharmacology 75: 227–234.

    Article  PubMed  CAS  Google Scholar 

  4. Uhlig, S., R. Goggel, and S. Engel. 2005. Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. Pharmacological Reports 57(suppl): 206–221.

    PubMed  Google Scholar 

  5. Vadas, P., M. Gold, B. Perelman, and G.M. Liss. 2008. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. The New England Journal of Medicine 358: 28–35.

    Article  PubMed  CAS  Google Scholar 

  6. Xu, W., S.H. Xia, H. Wang, H. Chen, and Y.L. Wang. 2007. Role of platelet activating factor in pathogenesis of acute respiratory distress syndrome. Chinese Medical Journal 120: 1840–1844.

    PubMed  Google Scholar 

  7. Karasawa, K. 2006. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochimica et Biophysica Acta 1761: 1359–1372.

    Article  PubMed  CAS  Google Scholar 

  8. Zalewski, A., and C. Macphee. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 923–931.

    Article  PubMed  CAS  Google Scholar 

  9. Ai, M., and M. Madjid. 2009. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiology 5: 159–173.

    Article  Google Scholar 

  10. Morgan, E.N., E.M. Boyle, W. Yun, and J.C. Kovacich. 1999. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100(19suppl): ll365–368.

    Google Scholar 

  11. Chris, J., D.S. Packard, S.J. Denis, and M.D. Reily. 2000. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. The New England Journal of Medicine 343: 1148–1155.

    Article  Google Scholar 

  12. Magjid, M., M. Ali, and J.T. Willerson. 2010. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Texas Heart Institute Journal 37: 25–39.

    Google Scholar 

  13. Karbina, S.A., and E. Ninio. 2006. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochimica et Biophysica Acta 1761: 1351–1358.

    Article  Google Scholar 

  14. Howard, K.M., M. Abdel, M. Ditmyer, and N. Pate. 2011. Lipopolysaccharide and platelet-activating factor stimulate expression of platelet activating factor acetylhydrolase via distinct signaling pathways. Inflammation Research 60: 735–744.

    Article  PubMed  CAS  Google Scholar 

  15. Chen, K.J., M. Xue, and H. Yin. 2008. The relationship between platelet activation and coronary heart disease and blood-stasis syndrome. Journal of Capital Medical University 29: 266–269.

    CAS  Google Scholar 

  16. Ren, J.X., J.X. Liu, C.R. Lin, et al. 2010. Comparative analysis on the biological basis of blood stasis syndrome induced by qi-stagnation and qi-deficiency in patients with unstable angina pectoris. Chinese Journal of Integrated Traditional and Western Medicine. 30: 352–356.

    PubMed  Google Scholar 

  17. Pen, W.J., Z.H. Xing, X. Liao, and W.P. Liu. 2011. Effect of Yiqi Huoxue therapy on serum IL-6, ICAM-1 and TNF-α in patients with stable angina pectoris in qi deficiency and blood stasis. Journal of Traditional Chinese Medicine University of Hunan. 31: 49–51.

    Google Scholar 

  18. Zhao, H.Y., W.H. Wang, W.Q. Chen, et al. 2011. Effect of Shanzha Xiaozhi capsule on homocysteine and hypersensitivity-C reactive protein in patients of non-acute coronary heart disease with phlegm and blood stasis syndrome. Journal of New Chinese Medicine 43: 9–11.

    Google Scholar 

  19. Ma, X.J., H.J. Yin, and K.J. Chen. 2007. Research progress of correlation between blood stasis syndrome and inflammation. CJITWM 27: 669–672.

    Google Scholar 

  20. Chignard, M., J.P. Le Couedic, M. Tence, B.B. Vargaftig, and J. Benveniste. 1979. The role of platelet-activating factor in platelet aggregation [J]. Nature 279: 799–800.

    Article  PubMed  CAS  Google Scholar 

  21. International Society of Cardiology. 1981. Naming and diagnostic criteria of ischaemic heart disease. Chinese Journal of Cardiology 9: 75–76.

    Google Scholar 

  22. Disease Special Committee, Chinese Association of the Integrative Medicine. Standard of syndrome differentiation on coronary heart disease of Chinese medicine. Chinese Journal of Integrated Traditional and Western Medicine (Chin), 1991; 11:257.

  23. Hanahan, D.J. 1986. Platelet activating factor: a biologically active phosphoglyceride. Annual Review of Biochemistry 55: 483–509.

    Article  PubMed  CAS  Google Scholar 

  24. Penna, C., E. Bassino, and G. Alloatti. 2011. Platelet activating factor: the good and bad in the ischemic/reperfused heart. Experimental Biology and Medicine 236: 390–401.

    Article  PubMed  CAS  Google Scholar 

  25. Montrucchio, G., G. Alloatti, and G. Camussi. 2000. Role of platelet-activating factor in cardiovascular pathophysiology. Physiological Reviews 80: 1669–1699.

    PubMed  CAS  Google Scholar 

  26. Gilli, U.O., M.K. Schneider, P. Loetscher, et al. 2005. Human polymorphonuclear neutrophils are recruited by porcine chemokines acting on CXC chemokine receptor 2, and platelet-activating factor. Transplantation 79: 1324–1331.

    Article  PubMed  CAS  Google Scholar 

  27. Subbanagounder, G., N. Leitinger, T. Peggy, and K.F. Shih. 1999. Evidence that phospholipids oxidation products and/or platelet activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circulation Research 85: 311–318.

    Article  PubMed  CAS  Google Scholar 

  28. Feng, W., T. Wu, Q.F. Sun, P.S. Yang, and X.L. Liu. 2010. Detection of platelet activating factor in unstimulated mixed saliva and gingival crevicular fluid of periodontitis patients with coronary heart disease. Shanghai Kou Qiang Yi Xue 19: 228–231.

    PubMed  CAS  Google Scholar 

  29. Chen, H., P. Zheng, J. Zhu, and L. Zhao. 2010. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clinical Oral Investigations 14: 629–636.

    Article  PubMed  Google Scholar 

  30. Garber, A.M., and A.L. Avins. 1994. Triglyceride concentration and coronary heart disease. BMJ 309: 1440–1442.

    Article  PubMed  CAS  Google Scholar 

  31. Oppenheimaer, G.M. 2006. Profiling risk: the emergence of coronary heart disease epidemiology in the United States. International Journal of Epidemiology 35: 720–730.

    Article  Google Scholar 

  32. Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic option. Nature Medicine 17: 1410–1422.

    Article  PubMed  CAS  Google Scholar 

  33. Xue, M., K.J. Chen, and H.J. Yin. 2008. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood stasis syndrome. Chinese Journal of Integrative Medicine 14: 267–273.

    Article  PubMed  CAS  Google Scholar 

  34. Tsantila, N., A.B. Tsoupras, E. Fragopoulou, and S. Antonopolou. 2011. In vitro and in vivo effects of stains on platelet-activating factor and its metalism. Angiology 62: 209–218.

    Article  PubMed  CAS  Google Scholar 

  35. Snyder, F. 1989. Biochemistry of PAF: a unique class of biologically active phospholipids. Proceedings of the Society for Experimental Biology and Medicine 190: 125–135.

    PubMed  CAS  Google Scholar 

  36. Maseri, A. 1997. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. The New England Journal of Medicine 336: 1014–1016.

    Article  PubMed  CAS  Google Scholar 

  37. Chen, Y.Z. 2006. The changed concentration of serum IL-6, IL-10 and CHD. Chinese Journal of Microecology. 18: 222–223.

    CAS  Google Scholar 

  38. Ren, N., T. Huang, J. Shu, J.B. Du, et al. 2007. Changes and prognostic value of serum high sensitivity C reactive protein and interleukin 6 levels in patients with acute coronary syndrome. Acta Academiae Medicinae CPAPF. 16: 497–501.

    CAS  Google Scholar 

  39. Pasceri, V., J.T. Willerson, and E.T. Yeh. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165–2168.

    Article  PubMed  CAS  Google Scholar 

  40. Zheng, F., D. Qu, H. Xu, et al. 2009. Relationship between Chinese medicine syndrome and serum level of high-sensitivity C-reactive protein in patients with stable coronary heart disease. CJJIWM 29: 485–489.

    CAS  Google Scholar 

  41. Arai, H. 2002. Platelet-activating factor acetylhydrolase. Prostaglandins & Other Lipid Mediators 68–69: 83–94.

    Article  Google Scholar 

  42. Macphee, C.H., K.E. Moores, H.F. Boyd, D. Dhanak, et al. 1999. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal 338: 479–487.

    Article  PubMed  CAS  Google Scholar 

  43. Tjoelker, L.W., and D.M. Stafforini. 2000. Platelet-activating factor acetylhydrolases in health and disease. Biochimica et Biophysica Acta 1488: 102–123.

    Article  PubMed  CAS  Google Scholar 

  44. Itabe, H. 1998. Oxidized phospholipids as a new landmark in atherosclerosis. Progress in Lipid Research 37: 181–207.

    Article  PubMed  CAS  Google Scholar 

  45. Carlquist, J.F., J.B. Muhlestein, and J.L. Anderson. 2007. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7: 511–7.

    Article  PubMed  CAS  Google Scholar 

  46. Caslake, M.J., C.J. Packard, K.E. Sucking, S.D. Holmes, et al. 2000. Lipoprotein-associated phospholipase A2 platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150: 413–419.

    Article  PubMed  CAS  Google Scholar 

  47. Samsamshariat, S., G. Basati, A. Movahedian, M. Pourfarzam, and N. Sarrafzadegan. 2011. Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. Journal of Research in Medical Sciences 16: 674–679.

    PubMed  CAS  Google Scholar 

  48. Persson, M., J.A. Nilsson, J.J. Nelson, B. Hedblad, and G. Berglund. 2007. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 190: 388–396.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by research funds from the National Natural Science Foundation of China (grant No: 81072726, National Natural Science Foundation of China, Beijing, China) and the Natural Science Foundation of Fujian province (grant No. 2009J01163, Fujian Provincial Department of Science and Technology, Fujian, China).

Author information

Authors and Affiliations

  1. Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, 350108, Fuzhou, China

    Guo-Hua Zheng, Li-Juan Mei, Hai-Ying Chen & Jian-Feng Chu

  2. Department of Cardiologic Medicine, The People’s Hospital of Fujian Province, Fuzhou, China

    Shang-Quan Xiong & Ting Wang

Authors
  1. Guo-Hua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shang-Quan Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Juan Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hai-Ying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian-Feng Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guo-Hua Zheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, GH., Xiong, SQ., Mei, LJ. et al. Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study. Inflammation 35, 1419–1428 (2012). https://doi.org/10.1007/s10753-012-9455-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10753-012-9455-4

KEY WORDS

Search

Navigation